VIDEO: Atogepant improved daily function, quality of life in adults with chronic migraine
Click Here to Manage Email Alerts
AUSTIN, Texas — Atogepant significantly improved daily functioning and reduced physical impairment in adults with chronic migraine within 1 week of treatment, according to study results presented here by Jessica Ailani, MD.
“Quality-of-life measures are very important for people with migraine, and in clinical practice ... when we’re evaluating how a person with migraine is doing in their day-to-day life,” Ailani, clinical professor of neurology at MedStar’s Georgetown University Hospital and director of the MedStar Georgetown Headache Center, told Healio at the American Headache Society Annual Scientific Meeting.
Researchers evaluated patient-reported data from 755 adults with chronic migraine who participated in the phase 3, multicenter, placebo-controlled PROGRESS trial. Participants were given atogepant 30 mg twice a day (n = 253) or 60 mg once a day (n = 256) or placebo (n = 246) for 12 weeks.
According to results, once-daily atogepant 60 mg improved performance of daily activities and reduced physical impairment as early as 1 week vs. placebo, while boosting quality of life within 2 weeks of administration.
“Clinically, this is extremely relevant: that you can start a patient on an oral treatment for chronic migraine and tell them ... [they] can get back to living a better life sooner,” Ailani said.